Pralsetinib Patent Expiration
Pralsetinib is used for advanced or metastatic RET fusion-positive thyroid cancer and non-small cell lung cancer in certain patients. It was first introduced by Rigel Pharmaceuticals Inc
Pralsetinib Patents
Given below is the list of patents protecting Pralsetinib, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Gavreto | US10030005 | Inhibitors of RET | Nov 01, 2036 | Rigel Pharms |
Gavreto | US11273160 | RET inhibitor for use in treating cancer having a RET alteration | Apr 03, 2039 | Rigel Pharms |
Gavreto | US11872192 | RET inhibitor for use in treating cancer having a RET alteration | Apr 03, 2039 | Rigel Pharms |
Gavreto | US11963958 | RET inhibitor for use in treating cancer having a RET alteration | Apr 03, 2039 | Rigel Pharms |
Coming Soon
Patent Strength Analyzer
![](/_nuxt/img/PatentAnalyzerAd.722976d.jpg)
YesNo
Thank you for your response 🥳